NY-PRICE-F(X)
Price f(x) , the global leader in cloud pricing software, has raised €25 million in Series B funding. Leading the round are Digital+ Partners, a leading European B2B technology growth investor, and Bain & Company, one of the world's top management consulting firms. The Series A investors, Prague-based Credo Ventures and London-based Talis Capital, also participated in the round.
Established in 2011 in Munich, Price f(x) provides a modular SaaS solution for Price Optimization, Management (PO&M) and Configure-Price-Quote (CPQ) for enterprises of any size, based on the latest in native cloud architecture. The company currently serves over 80 global, blue-chip B2B and B2C customers across a variety of industries, including Robert Bosch, SchneiderElectric, Owens-Illinois, Iron Mountain and Sonoco. Price f(x) has also developed a strong partner ecosystem with leading global technology, consulting and integration providers—including Bain & Company and SAP—enabling a best-in-class service offering, which helps customers realize a fast time-to-value on their pricing projects.
“Price f(x) has become the leading SaaS pricing solution provider on the market through its customer centric approach and by offering a feature-rich, highly flexible pricing tool that is also risk free and fast to implement,” said Marcin Cichon, CEO and co-Founder of Price f(x). “Our success is based on the continued satisfaction and loyalty of our customers. This new funding will allow us to help even more businesses to thrive by further expanding our existing platform capabilities and also introducing a new product offering for the SME market segment.”
“We have been very impressed by what Marcin and his team have achieved to date and see a huge growth opportunity ahead for Price f(x). They have built a world-class product, driven by a relentless customer focus, and we believe they are set to become the global market leader in pricing software. We are proud and excited to co-lead this round with Bain & Company and support Price f(x) in this next stage of growth”, said Axel Krieger, Founding Partner at Digital+ Partners.
Earlier this year, Bain & Company and Price f(x) announced a partnership to develop the Bain Pricing Navigator, offering Bain & Company clients a powerful, industry-leading software tool. The solution enables customers to continuously assess and adjust pricing based on their company’s performance by leveraging real-time dashboards, proprietary insights and templates, as well as integration with CRM and ERP systems.
“For most companies, pricing is the single most effective lever to boost earnings,” said Ron Kermisch , Bain & Company’s global pricing leader. “Yet many companies leave money on the table because they do not set the best price or ensure customers actually pay the price they have determined. Bain & Company sees investing in Price f(x) as a great opportunity to help Price f(x) to become the de-facto standard in pricing and with that to be also the best-of-breed competitive weapon for Bain’s clients, to stay at the cutting edge of pricing.”
Over the last decade, Bain & Company has developed a deep understanding of pricing strategy and a proven track record of results, working with B2B and B2C companies globally across industries. A Bain & Company survey of more than 1,700 pricing decision-makers found that 70 percent of companies believe pricing is a top management priority. However, more than half of respondents conclude that management has insufficient visibility into pricing decisions. Furthermore, fewer than 20 percent of the companies surveyed have appropriate tools and dashboards to improve pricing decisions.
Ondrej Bartos, Co-Founder & Managing Partner at Credo Ventures said, “Since investing in Price f(x) alongside Talis Capital in 2016, it’s been exciting to see the company close in on their vision to become the leader in price optimization software solutions. The energy and resilience demonstrated by Marcin and his team is what makes truly successful companies and we are grateful to be part of their journey.”
Price f(x) is a member of the Bain Alliance Ecosystem – a network of best-of-breed partnerships with complementary tool, technology, and service providers that accelerates delivery of breakthrough client results. Through the Bain Alliance Ecosystem, Bain & Company clients have access to relevant new capabilities, enabling faster assimilation of new ideas, skills, and ways of working.
###
About Price f(x)
Established in 2011 in Germany, Price f(x) AG is the provider of a full suite of price management and CPQ SaaS solution based on latest native cloud architecture, offering broad and flexible support to the entire price management closed loop cycle of Price Strategy, Controlling, Setting and Realization. The solution is suitable for B2B and B2C as well as for any industry, any size of business and geographical location. Price f(x)’s vision is to remain the leading SaaS pricing and CPQ platform provider through offering easy to use, fast to implement, flexible to adapt, risk free and inexpensive, comprehensive solutions. Price f(x)’s business model is entirely based on the satisfaction and loyalty of its customers. For more information please visit: www.pricefx.com .
About Digital+ Partners
Digital+ Partners is a leading technology growth equity investor focused on European and US technology companies with €350 million assets under management. Digital+ aims to support ambitious entrepreneurs build global technology companies, providing them with strategic advice and long-term financial support to help them define and execute their growth plans. The fund focuses exclusively on B2B technology companies and leverages a deep corporate network to help portfolio companies access new markets and build new partnerships. For more information please visit: http://www.dplus.partners .
About Bain & Company, Inc.
Bain & Company is the management consulting firm that the world's business leaders come to when they want results. Bain advises clients on strategy, operations, information technology, organization, private equity, digital transformation and strategy, and mergers and acquisition, developing practical insights that clients act on and transferring skills that make change stick. The firm aligns its incentives with clients by linking its fees to their results. Bain clients have outperformed the stock market 4 to 1. Founded in 1973, Bain has 57 offices in 36 countries, and its deep expertise and client roster cross every industry and economic sector. For more information visit: www.bain.com . Follow us on Twitter @BainAlerts .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005264/en/
Contact:
Price f(x) Marcin Cichon CEO +49 (0) 180 5-7742339 info@pricefx.eu
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom